These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28369518)

  • 21. Endoplasmic reticulum stress in myotonic dystrophy type 1 muscle.
    Ikezoe K; Nakamori M; Furuya H; Arahata H; Kanemoto S; Kimura T; Imaizumi K; Takahashi MP; Sakoda S; Fujii N; Kira J
    Acta Neuropathol; 2007 Nov; 114(5):527-35. PubMed ID: 17661063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing.
    Paul S; Dansithong W; Kim D; Rossi J; Webster NJ; Comai L; Reddy S
    EMBO J; 2006 Sep; 25(18):4271-83. PubMed ID: 16946708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.
    Crawford Parks TE; Marcellus KA; Péladeau C; Jasmin BJ; Ravel-Chapuis A
    Hum Mol Genet; 2020 Aug; 29(13):2185-2199. PubMed ID: 32504084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
    Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
    RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.
    Kuyumcu-Martinez NM; Wang GS; Cooper TA
    Mol Cell; 2007 Oct; 28(1):68-78. PubMed ID: 17936705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matching of calcineurin activity to upstream effectors is critical for skeletal muscle fiber growth.
    Dunn SE; Chin ER; Michel RN
    J Cell Biol; 2000 Oct; 151(3):663-72. PubMed ID: 11062266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Celf1 regulates cell cycle and is partially responsible for defective myoblast differentiation in myotonic dystrophy RNA toxicity.
    Peng X; Shen X; Chen X; Liang R; Azares AR; Liu Y
    Biochim Biophys Acta; 2015 Jul; 1852(7):1490-7. PubMed ID: 25887157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.
    Wang M; Weng WC; Stock L; Lindquist D; Martinez A; Gourdon G; Timchenko N; Snape M; Timchenko L
    Mol Cell Biol; 2019 Nov; 39(21):. PubMed ID: 31383751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative splicing alterations of Ca2+ handling genes are associated with Ca2+ signal dysregulation in myotonic dystrophy type 1 (DM1) and type 2 (DM2) myotubes.
    Santoro M; Piacentini R; Masciullo M; Bianchi ML; Modoni A; Podda MV; Ricci E; Silvestri G; Grassi C
    Neuropathol Appl Neurobiol; 2014 Jun; 40(4):464-76. PubMed ID: 23888875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.
    Morriss GR; Rajapakshe K; Huang S; Coarfa C; Cooper TA
    Hum Mol Genet; 2018 Aug; 27(16):2789-2804. PubMed ID: 29771332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing.
    Ravel-Chapuis A; Bélanger G; Yadava RS; Mahadevan MS; DesGroseillers L; Côté J; Jasmin BJ
    J Cell Biol; 2012 Mar; 196(6):699-712. PubMed ID: 22431750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy.
    Li M; Zhuang Y; Batra R; Thomas JD; Li M; Nutter CA; Scotti MM; Carter HA; Wang ZJ; Huang XS; Pu CQ; Swanson MS; Xie W
    Proc Natl Acad Sci U S A; 2020 Mar; 117(10):5472-5477. PubMed ID: 32086392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.
    Klein AF; Varela MA; Arandel L; Holland A; Naouar N; Arzumanov A; Seoane D; Revillod L; Bassez G; Ferry A; Jauvin D; Gourdon G; Puymirat J; Gait MJ; Furling D; Wood MJ
    J Clin Invest; 2019 Nov; 129(11):4739-4744. PubMed ID: 31479430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
    Dansithong W; Paul S; Comai L; Reddy S
    J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-type-specific dysregulation of RNA alternative splicing in short tandem repeat mouse knockin models of myotonic dystrophy.
    Nutter CA; Bubenik JL; Oliveira R; Ivankovic F; Sznajder ŁJ; Kidd BM; Pinto BS; Otero BA; Carter HA; Vitriol EA; Wang ET; Swanson MS
    Genes Dev; 2019 Dec; 33(23-24):1635-1640. PubMed ID: 31624084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Misregulation of alternative splicing and microRNA processing in DM1 pathogenesis].
    Furling D
    Rinsho Shinkeigaku; 2012; 52(11):1018-22. PubMed ID: 23196502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
    Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
    Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2.
    Botta A; Vallo L; Rinaldi F; Bonifazi E; Amati F; Biancolella M; Gambardella S; Mancinelli E; Angelini C; Meola G; Novelli G
    Gene Expr; 2007; 13(6):339-51. PubMed ID: 17708420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RBFOX1 cooperates with MBNL1 to control splicing in muscle, including events altered in myotonic dystrophy type 1.
    Klinck R; Fourrier A; Thibault P; Toutant J; Durand M; Lapointe E; Caillet-Boudin ML; Sergeant N; Gourdon G; Meola G; Furling D; Puymirat J; Chabot B
    PLoS One; 2014; 9(9):e107324. PubMed ID: 25211016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.
    Brockhoff M; Rion N; Chojnowska K; Wiktorowicz T; Eickhorst C; Erne B; Frank S; Angelini C; Furling D; Rüegg MA; Sinnreich M; Castets P
    J Clin Invest; 2017 Feb; 127(2):549-563. PubMed ID: 28067669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.